Search: (WFRF:(Lagergren Jesper))
> (2020-2024) >
Aspirin or statin u...
Aspirin or statin use in relation to survival after surgery for esophageal cancer : a population-based cohort study
-
- Holmberg, Dag (author)
- Karolinska Institutet
-
- Gottlieb-Vedi, Eivind (author)
- Karolinska Institutet
-
- Hedberg, Jakob, 1972- (author)
- Uppsala universitet,Gastrointestinalkirurgi,Uppsala Univ, Dept Surg Sci, Akad Sjukhuset, Uppsala, Sweden.
-
show more...
-
- Lindblad, Mats (author)
- Karolinska Institutet
-
- Mattsson, Fredrik (author)
- Karolinska Inst, Dept Mol Med & Surg, Retzius St 13A,4Th Floor, S-17177 Stockholm, Sweden.;Karolinska Univ Hosp, Retzius St 13A,4Th Floor, S-17177 Stockholm, Sweden.
-
- Lagergren, Jesper (author)
- Karolinska Institutet
-
show less...
-
(creator_code:org_t)
- BioMed Central (BMC), 2023
- 2023
- English.
-
In: BMC Cancer. - : BioMed Central (BMC). - 1471-2407. ; 23:1
- Related links:
-
https://uu.diva-port... (primary) (Raw object)
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Background: Adjuvant postoperative treatment with aspirin and statins may improve survival in several solid tumors. This study aimed to assess whether these medications improve the survival after curatively intended treatment (including esophagectomy) for esophageal cancer in an unselected setting.Methods: This nationwide cohort study included nearly all patients who underwent esophagectomy for esophageal cancer in Sweden from 2006 to 2015, with complete follow-up throughout 2019. Risk of 5-year disease-specific mortality in users compared to non-users of aspirin and statins was analyzed using Cox regression, providing hazard ratios (HR) with 95% confidence intervals (CI). The HRs were adjusted for age, sex, education, calendar year, comorbidity, aspirin/statin use (mutual adjustment), tumor histology, pathological tumor stage, and neoadjuvant chemo(radio)therapy.Results: The cohort included 838 patients who survived at least 1 year after esophagectomy for esophageal cancer. Of these, 165 (19.7%) used aspirin and 187 (22.3%) used statins during the first postoperative year. Neither aspirin use (HR 0.92, 95% CI 0.67-1.28) nor statin use (HR 0.88, 95% CI 0.64-1.23) were associated with any statistically significant decreased 5-year disease-specific mortality. Analyses stratified by subgroups of age, sex, tumor stage, and tumor histology did not reveal any associations between aspirin or statin use and 5-year disease-specific mortality. Three years of preoperative use of aspirin (HR 1.26, 95% CI 0.98-1.65) or statins (HR 0.99, 95% CI 0.67-1.45) did not decrease the 5-year disease-specific mortality.Conclusions: Use of aspirin or statins might not improve the 5-year survival in surgically treated esophageal cancer patients.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Esophageal neoplasm
- Chemoprevention
- Non-steroidal anti-inflammatory drugs
- Chemotherapy
- Adjuvant
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
BMC Cancer
(Search for host publication in LIBRIS)
To the university's database